Smaller Deals
Big Drugmakers Are Clinching Smaller Deals J&J, Merck and others are focusing on targets costing $5 billion or less, curtailing pricier acquisitions to help smooth regulators approval Aug. 12, 2024 5:30 am ET Merck has made four small acquisitions this year to diversify and deepen the companys drug pipeline. For years the worlds biggest drugmakers paid up for deals. Now they are writing much smaller checks. After shelling out tens of billions of dollars for single biotech companies, pharmaceutical giants such as AbbVie ABBV , AstraZeneca and Merck & Co. have shifted to smaller targets costing $5 billion or less. Many of the companies getting taken out are private. ------------------------------------------------ https://www.wsj.com/health/pharma/big-drugmakers-are-clinching-smaller-deals-0c039593?mod=pharma_more_article_pos12